サポート ブログ How Therapeutic Antibodies Are Produced: Identifying the Target Antigen

How Therapeutic Antibodies Are Produced: Identifying the Target Antigen

Biointron 2024-02-21 Read time: 3 mins
Antibody-Structure.jpg
Antigen binding site. DOI: 10.3390/antib8040055

Therapeutic antibodies are now targeting previously untreatable conditions like cancer, autoimmune diseases, and viral infections. This article delves into the process of creating these drugs, exploring their development from target identification to clinical application.

Identifying the Target Antigen

Developing a therapeutic antibody typically starts with finding a specific disease-associated antigen. These antigens are proteins expressed on the surface of pathogens or diseased cells, and the antibody’s specificity ensures it hits the right target with minimal collateral damage to healthy tissues. This maximizes the drug's efficacy and minimizes side effects.1

Biomedical researchers utilize various techniques to identify and validate target antigens. These include: 

  • Genomic and proteomic analyses: These techniques examine the genetic and protein makeup of diseased cells, pinpointing molecules uniquely associated with the disease. 

  • Immunological assays: These assess the ability of potential targets to trigger an immune response, a prerequisite for antibody-based therapy. 

  • High-throughput screening: This technology enables rapid testing of numerous potential targets, sifting through vast libraries of molecules. 

  • Bioinformatics: Powerful computational tools analyze vast datasets, helping researchers identify patterns and predict potential targets. 

  • Molecular biology techniques: These allow researchers to delve deeper, understanding the function and expression of potential targets within the disease context. 

One of the key challenges in this stage is distinguishing between antigens that are merely present in the disease state and those that play a critical role in disease progression.2

  • Disease relevance: Scientists need to ensure the target plays a causal role in disease progression, not just being a side effect or symptom. 

  • Drugability: The target should be accessible and structurally suitable for antibody binding and subsequent action. 

  • Specificity and tissue distribution: The target should be unique to the diseased cells, minimizing potential damage to healthy tissues. 

Further validation can also include:3

  • Functional studies: Understanding how the target protein contributes to disease and how its disruption might impact the disease process. 

  • Animal models: Testing the efficacy and safety of targeting the chosen antigen in living organisms. 

  • Predictive modeling: Utilizing computational tools to assess potential risks and side effects before moving to human trials.  

Biointron can help in your therapeutic antibody discovery. We provide services for VHH Antibody Discovery, Single B Cell Screening, and Hybridoma Sequencing. Learn more here: https://www.biointron.com/services/.


References:

  1. Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019). Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies, 8(4). https://doi.org/10.3390/antib8040055

  2. Emmerich, C. H., Gamboa, L. M., J. Hofmann, M. C., Bonin-Andresen, M., Arbach, O., Schendel, P., Gerlach, B., Hempel, K., Bespalov, A., Dirnagl, U., & Parnham, M. J. (2021). Improving target assessment in biomedical research: The GOT-IT recommendations. Nature Reviews. Drug Discovery, 20(1), 64-81. https://doi.org/10.1038/s41573-020-0087-3

  3. Pantaleo, G., Correia, B., Fenwick, C., Joo, V. S., & Perez, L. (2022). Antibodies to combat viral infections: Development strategies and progress. Nature Reviews. Drug Discovery, 21(9), 676-696. https://doi.org/10.1038/s41573-022-00495-3

Subscribe to our ブログ

Recent ブログ

The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.

Jul 12, 2024
ブログ

Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.

Jul 10, 2024
ブログ

Antibody-based assays are essential tools in biomedical research, providing the means to detect, quantify, and visualize specific proteins or antigens within complex biological samples. These assays' efficacy hinges on the antibodies' precise properties. While affinity, avidity, specificity, and selectivity are fundamental to antibody performance, the ultimate impact of these properties is heavily influenced by the experimental context in which the antibody is employed.

Jul 08, 2024
ブログ

Biologics, particularly antibodies, have become indispensable in biomedical research and therapeutic development. Research-use-only (RUO) biologics play a pivotal role in preclinical studies, providing researchers with the necessary tools to explore antibody functions and therapeutic potential in vivo.

Jul 04, 2024
ブログ

お客様の利便性を向上させるためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。